# A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes

> **NCT05693909** · PHASE2 · RECRUITING · sponsor: **Pharmacosmos A/S** · enrollment: 90 (estimated)

## Conditions studied

- Beta Thalassemia Major Anemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** SP-420

## Key facts

- **NCT ID:** NCT05693909
- **Lead sponsor:** Pharmacosmos A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-04
- **Primary completion:** 2027-10
- **Final completion:** 2028-05
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05693909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05693909, "A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05693909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*